Call Now Open

2025 Oxford-Harrington Rare Disease Scholar Award

You've just added:

Our Impact

How we're advancing cures globally

202

Medicines in the making

71

Institutions supported

43

Companies launched

21

Medicines in the clinic

15

Licenses to pharma

What sets us apart

In addition to receiving funding, every scholar is paired with a results-oriented and mission-focused team from our Therapeutics Development Center. Teams consist of a project manager and experienced pharma and business development advisors with a track record of bringing new drugs to market.

Learn More

Making discoveries partner-ready

Our pipeline represents the best science coming out of academic laboratories. Projects are selected for their innovation and potential for clinical impact. Our team proactively moves them forward to commercial viability and clinical use.

See All Discoveries

Accelerating Scientific Breakthroughs

By concentrating philanthropic, scientific, and business development resources during the high-risk stages of drug development, Harrington ‘de-risks’ therapeutic candidates and positions them for further investment and commercialization.

Learn More

The Latest

See All News
Synergy for Change Award to Morgan Stanley GIFT and Harrington Discovery Institute

Press Releases

Synergy for Change Award to Morgan Stanley GIFT and Harrington Discovery Institute

Award highlights collaboration between for profit and non-profit achieving great impact

Continue Reading
2023-2024 Harrington Annual Publication

Annual Publications

2023-2024 Harrington Annual Publication

Next Generation Medicines

Continue Reading
AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives  Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

Press Releases

AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survival

Continue Reading
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.